JP2014505095A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014505095A5 JP2014505095A5 JP2013553013A JP2013553013A JP2014505095A5 JP 2014505095 A5 JP2014505095 A5 JP 2014505095A5 JP 2013553013 A JP2013553013 A JP 2013553013A JP 2013553013 A JP2013553013 A JP 2013553013A JP 2014505095 A5 JP2014505095 A5 JP 2014505095A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally
- disease
- treatment
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 238000000034 method Methods 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 21
- 238000011282 treatment Methods 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 239000003085 diluting agent Substances 0.000 claims 9
- 230000007850 degeneration Effects 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 7
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 238000010511 deprotection reaction Methods 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 6
- 235000018102 proteins Nutrition 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 201000010374 Down Syndrome Diseases 0.000 claims 4
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 4
- 201000002832 Lewy body dementia Diseases 0.000 claims 4
- 229930195725 Mannitol Natural products 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 4
- 102100040243 Microtubule-associated protein tau Human genes 0.000 claims 4
- 208000027089 Parkinsonian disease Diseases 0.000 claims 4
- 206010034010 Parkinsonism Diseases 0.000 claims 4
- 241000710886 West Nile virus Species 0.000 claims 4
- 230000004931 aggregating effect Effects 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims 4
- 239000008101 lactose Substances 0.000 claims 4
- 239000000594 mannitol Substances 0.000 claims 4
- 235000010355 mannitol Nutrition 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000007909 solid dosage form Substances 0.000 claims 4
- 210000003523 substantia nigra Anatomy 0.000 claims 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 3
- -1 N-protected 3,7-diamino-10H-phenothiazine Chemical class 0.000 claims 3
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 238000007906 compression Methods 0.000 claims 3
- 230000006835 compression Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 102000014461 Ataxins Human genes 0.000 claims 2
- 108010078286 Ataxins Proteins 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 2
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims 2
- 206010013142 Disinhibition Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 208000027747 Kennedy disease Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 229920002774 Maltodextrin Polymers 0.000 claims 2
- 239000005913 Maltodextrin Substances 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 208000034799 Tauopathies Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000002776 aggregation Effects 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 210000004227 basal ganglia Anatomy 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 2
- 235000010216 calcium carbonate Nutrition 0.000 claims 2
- 239000001506 calcium phosphate Substances 0.000 claims 2
- 159000000007 calcium salts Chemical class 0.000 claims 2
- 235000011132 calcium sulphate Nutrition 0.000 claims 2
- 210000003591 cerebellar nuclei Anatomy 0.000 claims 2
- 210000003710 cerebral cortex Anatomy 0.000 claims 2
- 210000000349 chromosome Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000030381 cutaneous melanoma Diseases 0.000 claims 2
- 208000017004 dementia pugilistica Diseases 0.000 claims 2
- 239000008121 dextrose Substances 0.000 claims 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims 2
- 229940038472 dicalcium phosphate Drugs 0.000 claims 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000007908 dry granulation Methods 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- 229940035034 maltodextrin Drugs 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 208000005340 mucopolysaccharidosis III Diseases 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 230000001898 pallidal effect Effects 0.000 claims 2
- 230000009256 peri post natal development Effects 0.000 claims 2
- 229920000155 polyglutamine Polymers 0.000 claims 2
- 108010040003 polyglutamine Proteins 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 210000000463 red nucleus Anatomy 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000003708 skin melanoma Diseases 0.000 claims 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 229940032147 starch Drugs 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 235000000346 sugar Nutrition 0.000 claims 2
- 150000008163 sugars Chemical class 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 125000006585 (C6-C10) arylene group Chemical group 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 238000005054 agglomeration Methods 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 125000006242 amine protecting group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 238000007907 direct compression Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000011872 intimate mixture Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 229940098895 maleic acid Drugs 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 208000036709 mucopolysaccharidosis type 3B Diseases 0.000 claims 1
- 229960004838 phosphoric acid Drugs 0.000 claims 1
- 235000011007 phosphoric acid Nutrition 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000004845 protein aggregation Effects 0.000 claims 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000004334 sorbic acid Substances 0.000 claims 1
- 235000010199 sorbic acid Nutrition 0.000 claims 1
- 229940075582 sorbic acid Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 208000033556 type C1 Niemann-Pick disease Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000005550 wet granulation Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG201101060-0 | 2011-02-11 | ||
| SG2011010600 | 2011-02-11 | ||
| US201161485880P | 2011-05-13 | 2011-05-13 | |
| US61/485,880 | 2011-05-13 | ||
| PCT/GB2011/001221 WO2012107706A1 (en) | 2011-02-11 | 2011-08-15 | Phenothiazine diaminium salts and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016035263A Division JP6093890B2 (ja) | 2011-02-11 | 2016-02-26 | フェノチアジンジアミニウム塩およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014505095A JP2014505095A (ja) | 2014-02-27 |
| JP2014505095A5 true JP2014505095A5 (enExample) | 2014-09-18 |
| JP5898701B2 JP5898701B2 (ja) | 2016-04-13 |
Family
ID=44532939
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553013A Active JP5898701B2 (ja) | 2011-02-11 | 2011-08-15 | フェノチアジンジアミニウム塩およびそれらの使用 |
| JP2016035263A Active JP6093890B2 (ja) | 2011-02-11 | 2016-02-26 | フェノチアジンジアミニウム塩およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016035263A Active JP6093890B2 (ja) | 2011-02-11 | 2016-02-26 | フェノチアジンジアミニウム塩およびそれらの使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US9283230B2 (enExample) |
| EP (1) | EP2673266B1 (enExample) |
| JP (2) | JP5898701B2 (enExample) |
| KR (1) | KR101888713B1 (enExample) |
| CN (2) | CN103649061B (enExample) |
| AR (2) | AR082699A1 (enExample) |
| AU (1) | AU2011358840B2 (enExample) |
| BR (1) | BR112013020539A2 (enExample) |
| CA (1) | CA2827027C (enExample) |
| CY (1) | CY1118102T1 (enExample) |
| DK (1) | DK2673266T3 (enExample) |
| EA (1) | EA025033B1 (enExample) |
| ES (1) | ES2594703T3 (enExample) |
| HR (1) | HRP20161291T1 (enExample) |
| HU (1) | HUE031633T2 (enExample) |
| IL (2) | IL227736A (enExample) |
| LT (1) | LT2673266T (enExample) |
| MY (1) | MY165906A (enExample) |
| PL (1) | PL2673266T3 (enExample) |
| PT (1) | PT2673266T (enExample) |
| RS (1) | RS55237B1 (enExample) |
| SG (1) | SG192666A1 (enExample) |
| SI (1) | SI2673266T1 (enExample) |
| SM (1) | SMT201600389B (enExample) |
| WO (1) | WO2012107706A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104606199B (zh) | 2006-03-29 | 2022-09-13 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物盐及其用途 |
| CN101511803B (zh) | 2006-07-11 | 2012-10-31 | 维斯塔实验室有限公司 | 二氨基吩噻嗪*化合物的合成和/或纯化方法 |
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| JP5868955B2 (ja) | 2010-04-30 | 2016-02-24 | プロセッタ アンチバイラル インコーポレイテッド | 抗ウイルス化合物 |
| CA2827027C (en) | 2011-02-11 | 2019-06-04 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
| EP2699241B1 (en) | 2011-04-20 | 2016-07-27 | Prosetta Antiviral Inc. | Antiviral compounds |
| US9855276B2 (en) | 2012-10-25 | 2018-01-02 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| DK3033331T3 (da) * | 2013-08-15 | 2018-04-30 | Eupharma Pty Ltd | Fremgangsmåde til oprensning af diaminophenothiazinium forbindelser |
| AU2014340182B2 (en) | 2013-10-22 | 2019-05-23 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| JP2017518407A (ja) * | 2014-05-06 | 2017-07-06 | ミリケン・アンド・カンパニーＭｉｌｌｉｋｅｎ ＆ Ｃｏｍｐａｎｙ | ランドリーケア組成物 |
| BR112017021283A2 (en) * | 2015-04-16 | 2018-06-26 | Novartis Ag | ribocyclib tablet |
| GB201512678D0 (en) * | 2015-07-20 | 2015-08-26 | Wista Lab Ltd | Methods of chemical synthesis |
| CN105541756B (zh) * | 2015-12-17 | 2018-02-09 | 陕西方舟制药有限公司 | 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法 |
| CN106046027B (zh) * | 2016-06-30 | 2019-03-05 | 广东工业大学 | 一种含吡咯并吩噻嗪-1,3-二酮衍生物及其制备方法与应用 |
| PT3487505T (pt) | 2016-07-25 | 2023-06-07 | Wista Lab Ltd | Administração e dosagem de diaminofenotiazinas |
| EP3506894B1 (en) | 2016-08-31 | 2023-08-23 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
| GB201614834D0 (en) | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| GB201621817D0 (en) | 2016-12-21 | 2017-02-01 | Wista Lab Ltd | Methods of chemical synthesis |
| WO2019017995A1 (en) | 2017-07-20 | 2019-01-24 | Aztherapies, Inc. | FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN |
| JP6958860B2 (ja) | 2017-11-07 | 2021-11-02 | 学校法人自治医科大学 | ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途 |
| JP2021529771A (ja) | 2018-07-02 | 2021-11-04 | ザ ジェネラル ホスピタル コーポレイション | クロモリンナトリウムおよびα−ラクトースの粉末製剤 |
| WO2020014609A2 (en) | 2018-07-12 | 2020-01-16 | Hexamer Therapeutics Inc. | Self-assembling peptide scaffold |
| JP7465861B2 (ja) * | 2018-07-26 | 2024-04-11 | ウィスタ ラボラトリーズ リミテッド | 集団におけるジアミノフェノチアジンの最適化投与 |
| WO2020048593A1 (en) | 2018-09-05 | 2020-03-12 | Wista Laboratories Ltd. | Network methods for neurodegenerative diseases |
| US12383528B2 (en) | 2018-12-10 | 2025-08-12 | The General Hospital Corporation | Cromolyn esters and uses thereof |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| JP2023520580A (ja) | 2020-04-06 | 2023-05-17 | ザ ジェネラル ホスピタル コーポレイション | コロナウイルス誘発炎症状態の処置方法 |
| JP2023525512A (ja) | 2020-05-05 | 2023-06-16 | ウィスタ ラボラトリーズ リミテッド | Ｃｏｖｉｄ－１９の治療で使用されるメチルチオニニウム化合物 |
| GB202006659D0 (en) | 2020-05-05 | 2020-06-17 | Wista Lab Ltd | Therapeutic treatments |
| EP4146225B1 (en) * | 2020-05-05 | 2024-10-09 | WisTa Laboratories Ltd. | Methylthioninium compounds for use in the treatment of hypoxemia |
| GB202010652D0 (en) | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
| WO2022146914A1 (en) | 2020-12-28 | 2022-07-07 | The General Hospital Corporation | Cromolyn derivatives and uses thereof |
| CA3231484A1 (en) | 2021-10-01 | 2023-04-06 | Qinwen Mao | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
| KR102396975B1 (ko) | 2022-01-11 | 2022-05-12 | 이덕형 | 페이스 리프팅기 및 이를 위한 동작 방법 |
| GB202204185D0 (en) | 2022-03-24 | 2022-05-11 | Wista Lab Ltd | Oral treatment |
| WO2023202464A1 (zh) * | 2022-04-19 | 2023-10-26 | 英科隆生物技术（杭州）有限公司 | 一种电子媒介体的提纯方法 |
| CA3257856A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT) |
| EP4590275A1 (en) | 2022-09-21 | 2025-07-30 | WisTa Laboratories Ltd. | Novel formulations and vehicles |
| WO2024115630A1 (en) * | 2022-11-30 | 2024-06-06 | CERNY, Erich | Methylene blue for use in therapy of hepatitis b and/or hepatitis d infection |
| KR20250154422A (ko) | 2023-03-03 | 2025-10-28 | 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 | 미세혈관 뇌질환 치료를 위한 디아미노페노티아진 |
| WO2024224537A1 (ja) | 2023-04-27 | 2024-10-31 | ソシウム株式会社 | 筋萎縮性側索硬化症の治療又は予防剤 |
| WO2025041572A1 (ja) | 2023-08-18 | 2025-02-27 | ソシウム株式会社 | Ｔｄｐ－４３の凝集の抑制剤、ｔｄｐ－４３が過剰発現している細胞の細胞死の抑制剤、及びｔｄｐ－４３の凝集を伴う疾患の治療又は予防剤 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE569430A (enExample) | 1957-07-17 | |||
| US4309255A (en) | 1980-09-10 | 1982-01-05 | International Business Machines Corporation | Electrochromic recording paper |
| US4647525A (en) | 1984-10-01 | 1987-03-03 | Minnesota Mining And Manufacturing Company | Stabilized leuco phenazine dyes and their use in an imaging system |
| US4622395A (en) | 1984-10-01 | 1986-11-11 | Minnesota Mining And Manufacturing Company | Phenoxazine and phenothiazine dyes and leuco forms thereof |
| GB8724412D0 (en) | 1987-10-19 | 1987-11-25 | Medical Res Council | Protein |
| US4880373A (en) | 1988-04-28 | 1989-11-14 | The Upjohn Company | Tablet press |
| US5571666A (en) | 1988-10-28 | 1996-11-05 | Oklahoma Medical Research Foundation | Thiazine dyes used to inactivate HIV in biological fluids |
| CA2011116C (en) | 1989-03-06 | 1999-11-16 | Murray A. Kaplan | Lyophilized bmy-28142 dihydrochloride for parenteral use |
| US5220009A (en) | 1990-05-03 | 1993-06-15 | Yeda Research And Development Company Limited | Phenothiazinium salts and their use for disinfecting aqueous effluents |
| JPH0725786A (ja) | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
| AU2414092A (en) | 1991-08-01 | 1993-03-02 | Paul H. Voorheis | Diagnostic method for alzheimer's disease |
| WO1993003177A1 (en) | 1991-08-09 | 1993-02-18 | Massachusetts Institute Of Technology | Novel tau/neurofilament protein kinases |
| DE4140192C2 (de) | 1991-12-05 | 1996-02-29 | Alfatec Pharma Gmbh | Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen |
| WO1993011231A1 (en) | 1991-12-06 | 1993-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| JPH06289015A (ja) | 1993-03-30 | 1994-10-18 | Sunstar Inc | フェノチアジン系色源体安定化組成物 |
| GB9316727D0 (en) | 1993-08-12 | 1993-09-29 | Inst Of Psychiatry | Models of alzheimers's disease |
| GB9317193D0 (en) | 1993-08-18 | 1993-10-06 | Zeneca Ltd | Method |
| EP0778773A1 (en) | 1994-08-08 | 1997-06-18 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
| DE4430091A1 (de) | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von N-substituierten Phenothiazinen |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5804601A (en) | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
| US5693638A (en) | 1996-02-23 | 1997-12-02 | Myers; Daniel | Method of treating a migraine headache |
| US6333322B1 (en) | 1996-03-13 | 2001-12-25 | Eisai Co., Ltd. | Nitrogen-containing tricyclic compounds and drugs containing the same |
| EP0973383A4 (en) | 1997-01-21 | 2001-08-22 | American Nat Red Cross | INTRACELLULAR AND EXTRACELLULAR DECONTAMINATION OF WHOLE BLOOD AND BLOOD COMPONENTS WITH AMPHIPHILEN PHENOTHIAZINE-5-IUM DYES AND LIGHT |
| WO1999062548A1 (en) | 1998-06-01 | 1999-12-09 | Advanced Research And Technology Institute | Methods and compositions for diagnosing tauopathies |
| FR2788436A1 (fr) | 1999-01-14 | 2000-07-21 | Pf Medicament | Composition d'un derive de phenothiazine |
| WO2001053340A2 (en) | 2000-01-21 | 2001-07-26 | Pharmacia & Upjohn Company | Transgenic mouse model of human neurodegenerative disease |
| GB0017060D0 (en) | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| WO2003000714A2 (en) | 2001-06-22 | 2003-01-03 | Panacea Pharmaceuticals, Inc. | Compositions and methods for preventing protein aggregation in neurodegenerative diseases |
| GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| US7410965B2 (en) | 2002-05-29 | 2008-08-12 | Gruenenthal Gmbh | Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol |
| US6953974B2 (en) | 2003-08-26 | 2005-10-11 | Texas Instruments Incorporated | EEPROM device and method for providing lower programming voltage |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| AU2004295148A1 (en) | 2003-11-28 | 2005-06-16 | Photopharmica Limited | Developments in biologically active methylene blue derivatives (2) |
| JP5186212B2 (ja) | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
| ES2409683T3 (es) | 2004-09-23 | 2013-06-27 | Wista Laboratories Ltd. | Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT) |
| WO2006091728A2 (en) | 2005-02-24 | 2006-08-31 | The Trustees Of The University Of Pennsylvania | Microtubule stabilizing compounds and methods of their use |
| WO2007056439A1 (en) | 2005-11-08 | 2007-05-18 | Collegium Pharmaceutical, Inc. | Salts of methylene blue and its derivatives |
| DK2004155T3 (en) | 2006-03-29 | 2018-04-30 | Wista Lab Ltd | PROTEIN AGGREGATION INHIBITORS |
| DK2001556T3 (da) | 2006-03-29 | 2014-11-10 | Wista Lab Ltd | Thioninium-forbindelser og anvendelse deraf |
| CN104606199B (zh) | 2006-03-29 | 2022-09-13 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物盐及其用途 |
| CN101511803B (zh) | 2006-07-11 | 2012-10-31 | 维斯塔实验室有限公司 | 二氨基吩噻嗪*化合物的合成和/或纯化方法 |
| PL2167095T3 (pl) * | 2007-06-19 | 2019-11-29 | Wista Lab Ltd | Związki fenotiazynowe do leczenia łagodnych zaburzeń poznawczych |
| DK2205245T3 (en) * | 2007-10-03 | 2015-09-28 | Wista Lab Ltd | Therapeutic use of diaminophenothiaziner |
| CA2827027C (en) | 2011-02-11 | 2019-06-04 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
-
2011
- 2011-08-15 CA CA2827027A patent/CA2827027C/en active Active
- 2011-08-15 EA EA201391158A patent/EA025033B1/ru unknown
- 2011-08-15 BR BR112013020539A patent/BR112013020539A2/pt not_active Application Discontinuation
- 2011-08-15 AU AU2011358840A patent/AU2011358840B2/en active Active
- 2011-08-15 HR HRP20161291TT patent/HRP20161291T1/hr unknown
- 2011-08-15 ES ES11749476.5T patent/ES2594703T3/es active Active
- 2011-08-15 SG SG2013060132A patent/SG192666A1/en unknown
- 2011-08-15 KR KR1020137023810A patent/KR101888713B1/ko active Active
- 2011-08-15 PL PL11749476T patent/PL2673266T3/pl unknown
- 2011-08-15 PT PT117494765T patent/PT2673266T/pt unknown
- 2011-08-15 LT LTEP11749476.5T patent/LT2673266T/lt unknown
- 2011-08-15 JP JP2013553013A patent/JP5898701B2/ja active Active
- 2011-08-15 CN CN201180070054.XA patent/CN103649061B/zh active Active
- 2011-08-15 EP EP11749476.5A patent/EP2673266B1/en active Active
- 2011-08-15 WO PCT/GB2011/001221 patent/WO2012107706A1/en not_active Ceased
- 2011-08-15 US US13/984,841 patent/US9283230B2/en active Active
- 2011-08-15 SI SI201130992A patent/SI2673266T1/sl unknown
- 2011-08-15 RS RS20160880A patent/RS55237B1/sr unknown
- 2011-08-15 HU HUE11749476A patent/HUE031633T2/en unknown
- 2011-08-15 CN CN201610192816.8A patent/CN105853439A/zh active Pending
- 2011-08-15 DK DK11749476.5T patent/DK2673266T3/en active
- 2011-08-15 MY MYPI2013002933A patent/MY165906A/en unknown
- 2011-08-16 AR ARP110102969A patent/AR082699A1/es not_active Application Discontinuation
-
2013
- 2013-07-31 IL IL227736A patent/IL227736A/en active IP Right Grant
-
2016
- 2016-02-26 JP JP2016035263A patent/JP6093890B2/ja active Active
- 2016-02-29 US US15/056,610 patent/US9907804B2/en active Active
- 2016-10-17 CY CY20161101036T patent/CY1118102T1/el unknown
- 2016-10-27 SM SM201600389T patent/SMT201600389B/it unknown
- 2016-11-20 IL IL249056A patent/IL249056B/en active IP Right Grant
-
2018
- 2018-03-05 US US15/912,166 patent/US10864216B2/en active Active
-
2020
- 2020-01-24 US US16/751,811 patent/US11180464B2/en active Active
-
2021
- 2021-01-11 AR ARP210100056A patent/AR121016A2/es unknown
- 2021-10-12 US US17/499,498 patent/US12064439B2/en active Active
-
2024
- 2024-07-01 US US18/760,513 patent/US20250000871A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020203246B2 (en) | Polymorphs of selinexor | |
| CN103842330B (zh) | 抗炎的取代的环丁烯二酮化合物的胆碱盐 | |
| UA130623C2 (uk) | N4-гідроксицитидин та його похідні, а також пов'язані з ними варіанти противірусного застосування | |
| AU2017254523A1 (en) | Compounds and compositions for treating conditions associated with NLRP activity | |
| US20170105937A1 (en) | Olaparib co-precipitate and preparation method thereof | |
| US9447065B2 (en) | Pharmaceutical composition | |
| JP6001763B2 (ja) | 低用量エンテカビルの経口投与製剤の製造方法 | |
| JP2006527256A5 (enExample) | ||
| ES2606307T3 (es) | Producto de co-micronización que comprende acetato de ulipristal | |
| ES2355729T3 (es) | Nuevos polimorfos cristalinos del clopidogrel. | |
| JP2013522371A (ja) | Ｓｔ−２４６の多形型および調製方法 | |
| KR20150015500A (ko) | 엔테카비어의 약제학적 조성물 및 제조 방법 | |
| BRPI0706062A2 (pt) | rosuvastatina cálcica cristalina | |
| EP3817815A1 (en) | Nlrp modulators | |
| NZ548873A (en) | Stable amorphous forms of montelukast sodium | |
| JP2021028336A (ja) | アモルファステコビリマット調製 | |
| JP2019531314A (ja) | 右旋性オキシラセタムの新しい結晶型、調製方法、用途 | |
| US7351710B2 (en) | Preparation of amorphous form of indiplon | |
| EP3135666B1 (en) | (s)-oxiracetam crystal form iii, preparation method therefor, and application thereof | |
| US20080234323A1 (en) | Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride | |
| CN105307650B (zh) | 片剂形式的药物组合物及其制造方法 | |
| CA2990747C (en) | Phenyl amino pyrimidine compound or polymorph of salt thereof | |
| CN104292225A (zh) | 取代邻氨基苯甲酸小檗碱盐制备方法及用途 | |
| WO2005113492A1 (fr) | Sels d'ambroxol analogues de cysteine, procedes d'elaboration et utilisations | |
| TWI535444B (zh) | 熱休克蛋白抑制劑用於製備治療b型肝炎或肝癌之醫藥組合物的用途 |